BioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours

MT Newswires Live

Feb 20, 2025

BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.

Analysts polled by FactSet expected $0.74.

Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.

Analysts polled by FactSet expected $712.3 million.

For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.

BioMarin shares recently were up 8.2% in Wednesday's after-hours session.

Price: 71.00, Change: +5.39, Percent Change: +8.22

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2512434795"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512434795\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2512434795?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-20 05:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512434795","market":"sh","top_or_hot":-1,"title":"BioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours","media":"MT Newswires Live","content":"<html><body><p> BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.</p><p>Analysts polled by FactSet expected $0.74.</p><p>Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.</p><p>Analysts polled by FactSet expected $712.3 million.</p><p>For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.</p><p>BioMarin shares recently were up 8.2% in Wednesday's after-hours session.</p><p>Price: 71.00, Change: +5.39, Percent Change: +8.22</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioMarin Pharmaceutical Q4 Non-GAAP Earnings, Revenue Rise; 2025 Outlook Set -- Shares Up After Hours\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-20 05:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.</p><p>Analysts polled by FactSet expected $0.74.</p><p>Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.</p><p>Analysts polled by FactSet expected $712.3 million.</p><p>For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.</p><p>BioMarin shares recently were up 8.2% in Wednesday's after-hours session.</p><p>Price: 71.00, Change: +5.39, Percent Change: +8.22</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BMRN","symbol_name":"拜玛林制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2512434795","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512434795","pubTimestamp":1739999849,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.Analysts polled by FactSet expected $0.74.Revenue for the qua","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"BMRN":"拜玛林制药"},"translate_title":"拜玛林制药第四季度非公认会计准则盈利、收入增长；2025年展望设定——盘后股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BMRN":0.9},"content_text":"BioMarin Pharmaceutical (BMRN) late Wednesday reported Q4 non-GAAP earnings of $0.92 per diluted share, compared with $0.49 a year earlier.Analysts polled by FactSet expected $0.74.Revenue for the quarter ended Dec. 31 was $747.3 million, compared with $646.2 million a year earlier.Analysts polled by FactSet expected $712.3 million.For 2025, the company is projecting non-GAAP EPS of $4.20 to $4.40 on revenue of $3.1 billion to $3.2 billion. Analysts polled by FactSet are looking for $4.15 and $3.10 billion, respectively.BioMarin shares recently were up 8.2% in Wednesday's after-hours session.Price: 71.00, Change: +5.39, Percent Change: +8.22","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}